Terns Pharmaceuticals Inc

NASDAQ:TERNUnited States

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Contact Information

Headquarters

1065 East Hillsdale Blvd. Suite 100, Suite 100FOSTER CITY, CA, United States 94404

Phone

650-525-5535

Fax

650-275-4395

Executives

Independent Chairman of the Board

David Fellows

Chief Executive Officer, Director

Amy Burroughs

Chief Financial Officer, Treasurer

Mark Vignola

Chief Operating Officer, General Counsel, Secretary

Bryan Yoon

Chief Development Officer

Scott Harris